A α-synuclein aggregation inhibitor exerts neuroprotective effects via mitochondrial resilience in Parkinson's disease
{{output}}
Introduction: The pathogenesis of Parkinson's disease (PD) is driven by a vicious cycle of α-synuclein (α-Syn) aggregation and mitochondrial collapse. Breaking this pathogenic loop requires disease-modifying therapeutics capab... ...
